At the meeting of the LTS Supervisory Board on April 23rd 2018, Prof. Dr. Norbert Loos resigned as Chairman of the Supervisory Board of the LTS AG. Subsequently, the LTS AG Supervisory Board elected Prof. Dr. Christof Hettich as its new Chair­man. Remaining a regular member of the Supervisory Board of the LTS AG Prof. Loos will continue his close association with LTS.
Prof. Hettich has been a member of the Supervisory Board of the LTS AG since 2007. On the LTS Supervisory Board, Prof. Hettich represents dievini Hopp BioTech holding GmbH & Co. KG, of which he is the founding shareholder and managing di­rector. A lawyer and partner at RITTERSHAUS Rechtsanwälte in Mannheim / Frank­furt a. M./München, Prof. Hettich is also Chairman of the Management Board of SRH Holding. The Management Board of LTS congratulates Prof. Hettich to his election as chairman of the Supervisory Board of the LTS AG.

Prof. Loos chaired the Supervisory Board since 1999 and previously served on its predecessor, the advisory board of LTS Lohmann Therapie-Systeme GmbH. Building upon a distinguished academic career, Prof. Loos established BWK Unternehmens­beteiligungs GmbH as its managing partner. Prof. Loos` association with LTS com­menced as the representative for BWK, which was both a shareholder of LTS GmbH and later a shareholder of LTS AG. In his responsibilities as advisor as well as chair­man of the LTS supervisory board, Prof. Loos substantially shaped the positive de­velop­ment of LTS. The Management Board of LTS thanks Prof. Loos for many years of fruitful cooperation for the benefit of LTS.

About LTS Lohmann Therapie-Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.